Imara Stock News

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi

5 hot penny stocks to watch after big news. The post 5 Hot Penny Stocks To Watch After Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer, Inc. (NYSE: PFE) and BioNT

Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders

Expanding patient base and potential of Imara''s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression for targeted approach to a heterogeneous disease Study initiation planned for second quarter of 2022 BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ: IMRA ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687) to commence clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF). Imara plans to initiate a Phase 2 trial in the second quarter of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms. "We are excited to bring our deep expertise in clinical development and operations to patients suffering from HFpEF," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "We expect to initiate the Phase 2 trial in the second quarter of 2022, with a design that focuses on identifying HFpEF patients with high PDE9 expression, creating a targeted approach in this prevalent disease.

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to i

Imara Inc (IMRA) shares closed today at 1.6% above its 52 week low of $1.91, giving the company a market cap of $50M. The stock is currently down 13.8% year-to-date, down 86.0% over the past 12 months, and down 87.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 54.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 259.5% The company's stock price performance over the past 12 months lags the peer average by 172.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Imara Inc (IMRA) shares closed today at 1.5% above its 52 week low of $2.02, giving the company a market cap of $53M. The stock is currently down 8.9% year-to-date, down 84.7% over the past 12 months, and down 86.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 53.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 458.8% The company's stock price performance over the past 12 months lags the peer average by 181.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects sufferi

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 activation of Nrf2 increases HbF and F-cells, reduces VOCs and reduces markers of adhesion and hemolysis Beta-thalassemia mouse model shows IMR-261 increases hemoglobin and improves ineffective erythropoiesis BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ: IMRA ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced the presentation of data from its nuclear factor erythroid 2-related factor 2 (Nrf2) activator program, IMR-261, at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021. "I am excited by these preclinical data demonstrating the beneficial effect of IMR-261 in mouse models of sickle cell disease and beta-thalassemia," said Dr.

Great Valley Advisor Group Inc. lessened its position in shares of IMARA Inc. (NASDAQ:IMRA) by 14.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,411 shares of the companys stock after selling 4,800 shares during the quarter. Great Valley Advisor Group Inc. owned approximately []

Imara Inc (IMRA) shares closed today at 1.0% above its 52 week low of $3.06, giving the company a market cap of $86M. The stock is currently down 85.1% year-to-date, down 88.7% over the past 12 months, and down 78.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 74.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 170.3% The company's stock price performance over the past 12 months lags the peer average by 224.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Geode Capital Management LLC lessened its stake in shares of IMARA Inc. (NASDAQ:IMRA) by 51.0% during the second quarter, Holdings Channel.com reports. The firm owned 51,473 shares of the companys stock after selling 53,471 shares during the period. Geode Capital Management LLCs holdings in IMARA were worth $406,000 as of its most recent SEC filing. []